Recombinant Human KIR2DS2 protein (rFc Tag) (HPLC verified)

• Home
• Products
• Fusion Proteins
• AuthentiKine ELISA Kits
• Recombinant Human KIR2DS2 protein (rFc Tag) (HPLC verified) (Eg3746)

Species

Human

Purity

>90 %, SDS-PAGE
>90%, SEC-HPLC

Tag

rFc Tag

Activity

not tested

Cat no : Eg3746

---

Validation Data Gallery

• 

  Purity of Recombinant Human KIR2DS2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

• 

  The purity of Human KIR2DS2 was greater than 90% as determined by SEC-HPLC.

---

Product Information

• Purity: >90 %, SDS-PAGE; >90%, SEC-HPLC
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human KIR2DS2 protein His22-His245 (Accession# P43631) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 100132285
• Accession: P43631
• PredictedSize: 50.9 kDa
• SDS-PAGE: 55-70 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

KIR2DS2 is associated with reduced post-transplant recurrence and improved prognosis in solid tumors of hematologic malignancies and is an attractive target for NK-based therapeutic strategies. Furthermore, KIR2DS2 is associated with increased activation of anti-glioblastoma cells and improved clinical responses in breast, colorectal, non-small cell lung and hepatocellular carcinomas. (PMID: 35768150) Currently KIR2DS2 has been shown to directly recognize viral deconjugating peptides in the context of HLA-C and is protective against chronic hepatitis C virus infection. The high sequence homology between KIR2DS2 and inhibitory KIRs (KIR2DL2 and KIR2DL3) has made it difficult to develop an antibody that specifically detects KIR2DS2.

References:

1. Blunt MD, et al. J Immunol. 2022;209(2):379-390.                                                    
2. Graham LV, et al. Front Oncol. 2024;14:1404051.                                                   
3. Blunt MD, et al. HLA. 2019;93(1):32-35.